stockrow
Friday 6 November 2026
Export ADVB’s income statement to Excel — free account
Advanced Biomed Inc.
ADVB Healthcare Diagnostics & Research
Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00.
- EPS
- +174.2%
- Free cash flow
- −101.3%
Quarter to June 2026, against a year earlier
1.95
0.15
−7.14%
Follow ADVB
Alert me
Advanced Biomed Inc. (ADVB) P/E ratio
As of 5 November 2026, Advanced Biomed Inc. (ADVB) trades at a P/E ratio of 0.3×. Over the past ten years it has ranged from 0.0× (December 2025) to 3.2× (July 2026); the current reading is higher than 49% of that period. That is below the Diagnostics & Research industry median of 34.5× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.8× | — |
Against its own ten years
Low 0.0×
High 3.2×
Ten-year median
0.4×
Current reading's percentile
49
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DMTKQ DermTech, Inc. compare | n/m |
| ISPC iSpecimen Inc. compare | n/m |
| XWEL XWELL, Inc. compare | n/m |
| NDRA ENDRA Life Sciences Inc. compare | n/m |
| BIAF bioAffinity Technologies, Inc. compare | n/m |
| TTOO T2 Biosystems, Inc. compare | n/m |
| PRPH ProPhase Labs, Inc. compare | n/m |
| AWHL Aspira Women's Health Inc. compare | n/m |
| ADVB Advanced Biomed Inc. | 0.3× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)